Clinical Trial Safety Workbench
Free companion tools to Clinical Trial Safety for Medical Monitors and Safety Physicians: A Practical Guide to Medical Monitoring, SAEs, SUSARs, AESIs, RSI, Investigator Brochures, DSMBs, and Safety Management Plans by Hafez Selim, MD, PhD. Each tool follows a method from the book and opens with a worked example from its fictional trials.
Tools
Reporting clock calculator
US 7-day and 15-day, EU 7 + 8 and 15-day, the new clock when a case becomes life-threatening, aggregate findings and follow-up, each with its starting point.
Open the calculator →Reportability walkthrough, US and EU
One set of facts, two rules. Seriousness, endpoints, the (A)/(B)/(C) evidence routes, whose causality governs, expectedness and unblinding.
Walk through a case →Expectedness and RSI version tool
Finds the reference version in effect on the reaction date in each region, runs the four comparisons, and drafts both rationales.
Assess expectedness →Aggregate rate and trigger calculator
Exposure-adjusted rates with exact intervals, the blinded trigger check, and the unblinded rate ratio, rate difference and exact test.
Calculate rates →Liver case classifier and Hy's law plot
Multiples of ULN, R value and pattern for each case, with a peak ALT against bilirubin plot and the possible Hy's law range.
Classify liver cases →Causality timeline builder
Draw exposures, lab values and events on one axis, work through the seven elements, and copy the assessment or download the timeline.
Build a timeline →Templates
39 Word templates, one for every deliverable in the book: role map, Safety Management Plan outline, triage record, expectedness rationales, AESI specification and tracker, IND reportability memo, SUSAR log, reconciliation log, signal assessment, access log, DSMB timeline and response memo, escalation decision record, restart log, change package, CAPA check, and more. Each has a blank version and the book's worked example.
Browse and download templates →About the book
The book teaches the three questions that every serious case raises, and keeps them apart: what protects the participant now, what the evidence supports, and what must be reported, to whom and by when. It covers Phase I to III trials of drugs and biologics under a US IND and the EU Clinical Trials Regulation, from setting up the safety system to DSMB reviews, pauses, restarts and inspection. Published by Selim Medical Press.